SAB Biotherapeutics, Inc. Common Stock
$3.51
$0.01 (+0.29%)
$3.49Day Range$3.56
Key Statistics
Market Cap
$318.45M
Shares Outstanding
91.0M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 22, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$3.49
Day High
$3.56
Day Low
$3.49
Volume
1.96M
VWAP
$3.51
Prev Close
$3.50
Transactions
--
Acc. Volume
--
About SAB Biotherapeutics, Inc. Common Stock
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283686 employees777 W 41ST ST, MIAMI BEACH, FL, 33140305-845-2813IPO Oct 22, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001833214
- Composite FIGI
- BBG00YHY0G24
- Share Class FIGI
- BBG00YHY0GX0
- Ticker Root
- SABS
- SIC Code
- 2836
About SAB Biotherapeutics, Inc. Common Stock (SABS) Stock
SAB Biotherapeutics, Inc. Common Stock (SABS) closed the 2026-09-18 session at $3.51, up 0.29% versus the previous close (+0.01). The stock opened at $3.49 and traded between $3.49 and $3.56 during that session. Session trading volume was 2.0M shares. The volume-weighted average price (VWAP) is $3.51.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
SAB Biotherapeutics, Inc. Common Stock has a market capitalization of $318.5 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. SABS is listed on the XNAS exchange. The company employs approximately 86 people. SAB Biotherapeutics, Inc. Common Stock is headquartered in MIAMI BEACH, FL. The recorded listing date is 2021-10-22.
On this page you can find market SABS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.